Evaluation of Sensitivity and Resistance of Linezolid in Pre Extensively Drug Resistance Tuberculosis and Extensively Drug Resistance Tuberculosis at a Tertiary Care Hospital, Jamnagar, Gujarat, India
Published: November 1, 2019 | DOI: https://doi.org/10.7860/JCDR/2019/42544.13298
Dipali Maganbhai Gavali, Binita Aring, Summiya Mullan, Akhlakahemad A Nathametha, Abhishek B Dave
1. Senior Resident, Department of Microbiology, Shri M. P. Shah Medical Collage, Jamnagar, Gujarat, India.
2. Associate Professor, Department of Microbiology, Shri M. P. Shah Medical College, Jamnagar, Gujarat, India.
3. Professor and Head, Department of Microbiology, Shri M. P. Shah Medical College, Jamnagar, Gujarat, India.
4. Research Scientist-1, Department of Microbiology, Shri M.P.Shah Medical College, Jamnagar, Gujarat, India.
5. Research Scientist-2, Department of Microbiology, Shri M.P.Shah Medical College, Jamnagar, Gujarat, India.
Correspondence
Dr. Dipali Maganbhai Gavali,
Department of Microbiology, 1st Floor, Mental Hospital Campus on Vikas Gruh Road, Jmanagar-361001, Gujarat, India.
E-mail: dr.dipaligavli@gmail.com
Introduction: The diseases have a high prevalence in India, accounting for one fourth of the Tuberculosis (TB) cases in the world. The situation becomes more complicated due to the rising of Human Immunodeficiency virus/AIDS pandemic, the emergence of Multidrug- Resistance (MDR) TB, Pre Extensively Drug Resistance (Pre-XDR) TB, and Extensively Drug Resistance (XDR) TB. Therefore, new anti-TB drugs are urgently needed to treat MDR-TB, Pre XDR-TB, and XDR-TB. Linezolid was the first oxazolidinone compound licensed for clinical use.
Aim: To evaluate the sensitivity and resistance of linezolid in Pre XDR-TB and XDR-TB patients at a tertiary care hospital, Jamnagar, Gujarat, India.
Materials and Methods: This was a prospective study conducted from May 2017 to January 2018. Total sample received were 590 MDR-TB suspected cases. All samples were proceeded for rapid detection of MDR of Mycobacterium tuberculosis by direct Drug Susceptibility Testing (DST) using Bactec MGIT 960 system.
Results: Out of the total 590 samples, 468 were culture positive among this: 14 (3%) were linezolid resistance, 9 were Pre XDR-TB with linezolid resistance, 03 were XDR-TB with linezolid resistance and 2 were only linezolid resistance. A total of 454 (97%) were linezolid sensitive, 143 were Pre XDR-TB with linezolid sensitive and 19 were XDR-TB with linezolid sensitive. A total of 14 (3%) were HIV infected of which 2 had Pre XDR-TB and 1 had XDR-TB. All 14 were linezolid sensitive.
Conclusion: The present study showed that linezolid was found to be highly sensitive (97%) with low (3%) resistance in MDR-suspected patients. Linezolid is effective in treatment of MDR-TB, Pre XDR-TB and XDR-TB patient, but while receiving linezolid, patients should be closely monitored for signs or symptoms of bone marrow toxicity and peripheral and optic neuropathy.
[
FULL TEXT ] | [ PDF]